ISPOR CEO NANCY BERG NAMED A PHARMAVOICE 100

Published Aug 8, 2016
Annual List Recognizes Inspirational Individuals Who Have Made Positive Contributions to the Life Sciences Industry  Princeton, NJ—August 8, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced that its Chief Executive Officer Nancy Berg has been named a 2016 PharmaVOICE 100. The PharmaVOICE 100 was established twelve years ago by PharmaVOICE magazine and is an annual list of inspirational individuals recognized for their positive contributions to the life sciences industry. The PharmaVOICE 100 honorees represent a broad cross-section of the global life-sciences industry, including pharmaceutical, biopharmaceutical, biotechnology, contract research, clinical trial, research and development, patient education, advertising, digital, marketing, technology, academia, and many other sectors. This diverse group of individuals also represents a wide variety of functional areas ranging from the clinic to the C-suite. Berg assumed the role of CEO and Executive Director of ISPOR, a non-profit organization based in central New Jersey, in 2014. Over the past 20 years, ISPOR has become a the leading global scientific and educational organization for health economics and outcomes research (HEOR). PharmaVOICE highlights Berg’s forward-thinking and strategic leadership as a key to positioning ISPOR as a global leader in HEOR. "This must-read issue has become one of the most-anticipated and highly regarded publications of the year, and it is our great pleasure to showcase the 100 men and women who are demonstrating inspired leadership, innovating across the ecosystem, creating transformative change, disrupting the status quo, and building relationships to position the industry in the best way possible to serve the ultimate stakeholders: patients," said Taren Grom, Editor and Co-founder of PharmaVOICE. “I am deeply honored to be among the PharmaVOICE 100 leaders recognized this year,” noted Berg. “ISPOR’s members play an essential role in improving health care by bringing research excellence into the everyday health decisions that impact patients’ lives. It is a true honor to serve the Society at a time when the importance of HEOR has never been greater.”

###

Related Stories

ISPOR Releases Emerging Good Practices Guidance on Quantifying Specialized Knowledge in Healthcare

Nov 6, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that identifies existing structured expert elicitation protocols that can support healthcare decision making and provides important insights on how to choose which protocols may be the most appropriate for different scenarios, such as time-constrained decisions, early-stage technology assessments, and public health policies.

ISPOR Announces 2024 Health Economics and Outcomes Research Award Honorees

Oct 14, 2024

ISPOR—The Professional Society for Health Economics and Outcomes Research announced today the recipients of its 2024 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards.

Cracking the Code on Medicare's Drug Price Negotiations

Oct 1, 2024

ISPOR announced the publication of a study that provides estimates of how the Centers for Medicare & Medicaid Services (CMS) may have determined initial price offers for the first 10 drugs selected for Medicare price negotiation. A prepublication version of the study was released online on the same day the CMS announced it reached agreements for lower drug prices.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×